Hepatitis B virus: Molecular virology and common mutants

Seminars in Liver Disease

Volumn 26, Issue 2, 2006, Pages 87-96

  Harrison, Tim J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody escape; Antiviral resistance; Basic core promoter mutations; Precore mutants; Reverse transcriptase; Virus replication

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; DEOXYGUANOSINE DERIVATIVE; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOCAPSID PROTEIN; NUCLEOSIDE ANALOG; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; OPEN READING FRAME; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; VIRUS GENOME; VIRUS HEPATITIS; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MUTATION; RNA, VIRAL; VIRUS REPLICATION;

EID: 33646368672     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939754     Document Type: Review

References (70)

1. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289-309
2. Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes. Vaccine 2005;23:2409-2423
3. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-4402
4. Harrison TJ, Oon CJ, Zuckerman AJ. A novel antibody escape variant (ala 144) of hepatitis B virus in an identical twin before selection in the mother. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag; 1994:248-251
5. Sen N, Cao F, Tavis JE. Translation of duck hepatitis B virus reverse transcriptase by ribosomal shunting. J Virol 2004;78: 11751-11757
6. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983;3:656-662
7. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-591
8. Brunetto MR, Stemler M, Bonino F, et al. A new hepatitis-B virus strain in patients with severe anti-Hbe positive chronic hepatitis-B. J Hepatol 1990;10:258-261
9. Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990;64:1298-1303
10. Tong SP, Li JS, Vitvitski L, Trepo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology 1990; 176:596-603
11. Fiordalisi G, Cariani E, Mantero G, et al. High genomic variability in the pre-C region of hepatitis B virus in anti-HBe, HBV DNA-positive chronic hepatitis. J Med Virol 1990;31:297-300
12. Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrison TJ. Precore and core mutations in HBV from individuals in India with chronic infection. J Med Virol 1995;45:321-325
13. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant-possible contribution of a single nucleotide in the precore region. J Virol 1993;67:5402-5410
14. Aikawa T, Kanai K, Kako M, et al. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild-type virus and precore mutant. J Viral Hepat 1995;2:243-250
15. Lampertico P, Delninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of Interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997;26:1621-1625
16. Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994;68:8102-8110
17. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation, J Virol 1999;73:1239-1244
18. Takahashi K, Aoyama K, Ohno N, et al. The precore core promoter mutant (T(1762)A(1764)) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995;76:3159-3164
19. Hsia CC, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996;348:625-626
20. Fang ZL, Ling R, Wang SS, Nong J, Huang CS, Harrison TJ. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China. J Med Virol 1998;56:18-24
21. Fang ZL, Yang JY, Ge XM, et al. Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China. J Med Virol 2002;68:33-40
22. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124:327-334
23. Gunther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H. Type, prevalence, and significance of core promoter/ enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 1996; 70:8318-8331
24. Sendi H, Mehrab-Mohseni M, Zali MR, Norder H, Magnius LO. T-1764 G(1766) core promoter double mutants are restricted to hepatitis B virus strains with an A(1757) and are common in genotype D. J Gen Virol 2005;86:2451-2458
25. Beath SV, Boxall EH, Watson RM, Tarlow MJ, Kelly DA. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ 1992;304:1169-1170
26. Fagan EA, Smith PM, Davison F, Williams R. Fulminant hepatitis B in successive female sexual partners of two anti-HBe-positive males. Lancet 1986;2:538-540
27. Oren I, Hershow RC, Ben Porath E, et al. A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Med 1989;110:691-698
28. Kojima M, Shimizu M, Tsuchimochi T, et al. Posttransfusion fulminant hepatitis B associated with precore-defective HBV mutants. Vox Sang 1991;60:34-39
29. Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-248
30. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-1709
31. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology 1999;29: 1252-1258
32. Sterneck M, Gunther S, Santantonio T, et al. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology 1996;24:300-306
33. Friedt M, Gerner P, Wintermeyer P, Wirth S. Complete hepatitis B virus genome analysis in HBsAg positive mothers and their infants with fulminant hepatitis B. BMC Gastroenterol 2004;4:11
34. Takahashi K, Akahane Y, Gotanda T, et al. Demonstration of hepatitis B e antigen in the core of Dane particles. J Immunol 1979;122:275-279
35. Ehata T, Omata M, Yokosuka O, Hosoda K, Ohto M. Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis-B virus infection. J Clin Invest 1992;89:332-338
36. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52:25-137
37. Suk FM, Lin MH, Newman M, et al. Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (197L) in human hepatitis B virus. J Virol 2002;76:12069-12077
38. Le Pogam S, Yuan TT, Sahu GK, Chatterjee S, Shih C. Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol 2000;74:9099-9105
39. Rossner MT. Review, hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 1992;36: 101-117
40. Bruss V, Lu XY, Thomssen R, Gerlich WH. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J 1994;13:2273-2279
41. Lambert C, Mann S, Prange R. Assessment of determinants affecting the dual topology of hepadnaviral large envelope proteins. J Gen Virol 2004;85:1221-1225
42. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986;46:429-436
43. Chen YCJ, Delbrook K, Dealwis C, Mimms L, Mushahwar IK, Mandecki W. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci U S A 1996;93:1997-2001
44. Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol 1987;61:3030-3034
45. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-329
46. Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13:699-702
47. McMahon G, Ehrlich PH, Moustafa ZA, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992;15:757-766
48. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-222
49. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-263
50. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology 1993;194: 137-148
51. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-415
52. Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983;305:827-829
53. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757
54. Lok ASF, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722
55. Ling R, Mutimer D, Ahmed N, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24: 711-713
56. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717
57. Buti M, Jardi R, Cotrina M, Rodriguezfrias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol 1998;28:510-513
58. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633
59. Ling R, Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 1999;80:601-606
60. Niesters HGM, Deman RA, Pas SD, Fries E, Osterhaus ADME. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002;51:695-699
61. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003;10:256-265
62. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134
63. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-290
64. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297
65. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-1089
66. Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother 2005;55:608-611
67. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-3208
68. Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 2005;21:1845-1856
69. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-313
70. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299: 88-99